Neurodegenerative disease: Two-for-one on potential therapies

Affiliations

Comment

Ke Zhang et al. Nature. 2017.

. 2017 Apr 20;544(7650):302-303.

doi: 10.1038/nature21911. Epub 2017 Apr 12.

¹ Brain Science Institute, Johns Hopkins University, Baltimore, Maryland 21205, USA.

No abstract available

Comment on

Therapeutic reduction of ataxin-2 extends lifespan and reduces pathology in TDP-43 mice.
Becker LA, Huang B, Bieri G, Ma R, Knowles DA, Jafar-Nejad P, Messing J, Kim HJ, Soriano A, Auburger G, Pulst SM, Taylor JP, Rigo F, Gitler AD. Becker LA, et al. Nature. 2017 Apr 20;544(7650):367-371. doi: 10.1038/nature22038. Epub 2017 Apr 12. Nature. 2017. PMID: 28405022 Free PMC article.
Antisense oligonucleotide therapy for spinocerebellar ataxia type 2.
Scoles DR, Meera P, Schneider MD, Paul S, Dansithong W, Figueroa KP, Hung G, Rigo F, Bennett CF, Otis TS, Pulst SM. Scoles DR, et al. Nature. 2017 Apr 20;544(7650):362-366. doi: 10.1038/nature22044. Epub 2017 Apr 12. Nature. 2017. PMID: 28405024 Free PMC article.